The teens will be added to an ongoing study of the vaccine in adults that began last September, the New Brunswick, New Jersey-based drugmaker said Friday.
After initial data from the older teens is reviewed, the trial will expand to add adolescents ages 12 to 15.
The study is testing the safety and efficacy of both one-dose and two-dose regimens of the vaccine, with the two-dose regimens being studied at intervals of one, two and three months after the first shot.
Dr Mathai Mammen, global head of research and development for the company’s Janssen pharmaceuticals unit, says it also expects to initiate studies in pregnant women and children.
A total of 100 million J&J doses are pledged for the US by late May or June.